share_log

JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target

JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target

JMP证券重申Larimar Therapeutics的市场跑赢大盘,维持25美元的目标股价
Benzinga ·  03/15 10:37

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintains $25 price target.

JMP证券分析师乔纳森·沃勒本重申了Larimar Therapeutics(纳斯达克股票代码:LRMR)的市场跑赢大盘,并维持25美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发